"The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
VePesid (etoposide) is contraindicated in patients who have demonstrated a previous hypersensitivity to etoposide or any component of the formulation.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 9/18/2008
Additional VePesid Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.